Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan

Pacira BioSciences, Inc.

2024-FY EPS reported -$2.15 revenue$700,966,000

FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.
EXPAREL net sales $549.0M, ZILRETTA $118.1M, iovera° $22.8M for full year.
Unveils 5x30 plan: treat >3M patients/year, double-digit revenue CAGR, 5pp gross margin improvement by 2030.
Inducement grants: options for 20,300 shares and RSUs for 30,400 shares at $18.40.
Revenue preliminary and unaudited; full Q4 and FY results with guidance expected Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.